Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide

Transfusion Science

Volumn 19, Issue SUPPL., 1997, Pages 43-46

  Flachenecker, Peter ^a   Taleghani, Behrouz Mansouri ^a   Gold, Ralf ^a   Grossmann, Ralf ^a   Wiebecke, Dieter ^a   Toyka, Klaus Viktor ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; NICOTINIC RECEPTOR; POLYVINYL ALCOHOL; PROTEIN A;

ADOLESCENT; AUTOIMMUNE DISEASE; CASE REPORT; CONFERENCE PAPER; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOADSORPTION; INTRAVENOUS DRUG ADMINISTRATION; MAINTENANCE THERAPY; MUSCLE STRENGTH; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; PLASMAPHERESIS; REMISSION;

EID: 0031929056     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(97)00102-1     Document Type: Conference Paper

References (16)

1. Toyka KV, Drachman DB, Pestronk A, Kao I: Myasthenia gravis: passive transfer from man to mouse. Science 1975; 190:397-399.
2. Pinching AJ, Peters DK, Newsom Davis J: Remission of myasthenia gravis following plasma exchange. Lancet 1976; 2:1373-1376.
3. Drachman DB: Myasthenia gravis. N Engl J Med 1994; 330:1797-1810.
4. Hohlfeld R, Toyka KV, Heininger K, Grosse-Wilde H, Kalies I: Autoimrnune human T lymphocytes specific for acetylcholine receptor. Nature 1984; 310:244-246.
5. Hohlfeld R, Wekerle H: The thymus in myasthenia gravis. Neurol Clin 1994; 12:331-342.
6. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duanne DD: Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26:1954-1059.
7. Besinger UA, Toyka KV, Hoemberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A: Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983; 33:1316-1321.
8. Hohlfeld R, Toyka KV: Therapies, in de Baets MH, Oosterhuis HJGH (eds) Myasthenia Gravis. Boca Raton, CA. CRC Press, 1993, pp. 235-261.
9. Toyka KV, Muellges W: Myasthenia gravis and Lambert-Eaton myasthenic syndrome, in Hacke W (ed.): Neurocritical Care. Berlin, Springer-Verlag, 1994, pp. 807-815.
10. Heininger K, Hendricks M, Toyka KV: Myasthenia gravis: a new semiselective procedure to remove acetylcholine receptor autoantibodies from plasma. Plasma Ther Transfus Technol 1985; 6:771-775.
11. Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S: Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry 1994; 57:578-581.
12. Grob D, Simpson D, Mitsumoto H, et al.: Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995; 45:338-344.
13. Gjorstrup P, Watt RM: Therapeutic protein A immunoadsorption. A review. Transfus Sci 1990; 11:281-302.
14. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318:1423-1431.
15. Bijsterbosch MK, Klaus GGB: Cross-linking of surface immunoglobulin and Fc receptors on B lymphocytes inhibit stimulation of inositol phospholipid breakdown via the antigen receptors. J Exp Med 1985; 162:1825-1836.
16. Antozzi C, Berta E, Confalonieri P, Zuffi M, Cornelio F, Mantegazza R: Protein-A immunoadsorption in immunosuppression-resistant myasthenia gravis (letter). Lancet 1994; 343:124.